Through various phases of development with global or regional focus

Whether that is through co-development or a discovery partnership to uncover novel opportunities

We love a creative challenge and can be flexible to develop your asset with an enhanced patient selection or combination strategy

The Pathos Difference

We have built a proprietary platform called PathOS™ to gain crucial insights and act on them at scale. Our approach combines insilico analyses using a genetically validated framework with biological patient-derived models to design clinical trials optimized for speed, patient response, and, ultimately, drug approval.
We identify and define the pathways that drive and modulate oncogenesis and progression.
We leverage real-world data to stratify patients into more precisely defined population groups, test assumptions with contemporaneous data, and develop new therapeutic strategies or combinations targeted to each group to improve the probability of success.

Harnessing the promise and power of AI to accelerate drug development.

Join Pathos